In gastric cancer, results from a FLOT4 clinical trial suggest that the FLOT (fluorouracil/leucovorin, oxaliplatin, and docetaxel [Taxotere]) regimen should be the primary adjuvant treatment in gastric cancer over epirubicin/cisplatin/fluorouracil (ECF) or epirubicin/cisplatin/oxaliplatin (ECX). The trial showed that overall survival was longer for patients assigned to FLOT compared with ECF/ ECX (50 vs 35 months) and are predicted to be more effective for survival long term. Side effects like infections, diarrhea, and neutropenia took place more frequently with FLOT arm but patients receiving ECF/ECX had higher rates of vomiting and nausea. The 2 groups had nearly the same rates of serious adverse events and toxic deaths.
Treatment Options
View Full Article
Related Videos